| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $99,510 ) |
| | 2024 | 2024 | NAPROGENIX INC | 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 000 | 5 | NIH | 11/17/2023 | $99,510 |
|
| Issue Date FY: 2023 ( Subtotal = $993,323 ) |
| | 2023 | 2023 | NAPROGENIX INC | 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 002 | 5 | NIH | 8/29/2023 | $993,323 |
| | 2023 | 2022 | NAPROGENIX INC | 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 000 | 5 | NIH | 6/6/2023 | $0 |
| | 2023 | 2022 | NAPROGENIX INC | 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 001 | 4 | NIH | 5/26/2023 | $0 |
| | 2023 | 2022 | NAPROGENIX INC | 145 GRAHAM AVE | LEXINGTON | KY | 40506 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 000 | 4 | NIH | 1/10/2023 | $0 |
| | 2023 | 2022 | NAPROGENIX INC | 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44NS108804 | Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | 000 | 4 | NIH | 8/16/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,988,912 ) |
| | 2022 | 2022 | NAPROGENIX INC | 145 GRAHAM AVE | LEXINGTON | KY | 40506 | FAYETTE | USA | R44NS108804 | Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | 000 | 4 | NIH | 8/19/2022 | $617,512 |
| | 2022 | 2022 | NAPROGENIX INC | 145 GRAHAM AVE | LEXINGTON | KY | 40506 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 001 | 4 | NIH | 8/20/2022 | $1,404,983 |
| | 2022 | 2022 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 000 | 5 | NIH | 4/26/2022 | $966,417 |
| | 2022 | 2021 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 000 | 3 | NIH | 11/11/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,609,799 ) |
| | 2021 | 2021 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44NS108804 | Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | 001 | 3 | NIH | 8/13/2021 | $617,521 |
| | 2021 | 2021 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 000 | 4 | NIH | 4/9/2021 | $975,562 |
| | 2021 | 2021 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 001 | 3 | NIH | 8/31/2021 | $1,016,716 |
| | 2021 | 2021 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 003 | 3 | NIH | 9/22/2021 | $377,402 |
| | 2021 | 2020 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44NS108804 | Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | 000 | 2 | NIH | 10/27/2020 | $0 |
| | 2021 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 002 | 2 | NIH | 9/22/2021 | -$377,402 |
| | 2021 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 000 | 2 | NIH | 7/8/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,495,802 ) |
| | 2020 | 2020 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 001 | 3 | NIH | 4/3/2020 | $890,494 |
| | 2020 | 2020 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 003 | 3 | NIH | 8/27/2020 | $0 |
| | 2020 | 2020 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 002 | 3 | NIH | 8/26/2020 | $0 |
| | 2020 | 2020 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44NS108804 | Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | 000 | 2 | NIH | 9/20/2020 | $624,004 |
| | 2020 | 2020 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 004 | 3 | NIH | 9/4/2020 | $140,059 |
| | 2020 | 2019 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 000 | 2 | NIH | 1/20/2020 | -$80,348 |
| | 2020 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 000 | 2 | NIH | 8/7/2020 | $0 |
| | 2020 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AT008312 | Harvesting specific plant metabolites from hairy root cultures using magnetized nanoparticles | 000 | 3 | NIH | 7/27/2020 | -$78,407 |
| | 2020 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R43NS108804 | Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | 000 | 1 | NIH | 8/17/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $104,999 ) |
| | 2019 | 2019 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 000 | 2 | NIH | 2/27/2019 | $104,999 |
| | 2019 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 000 | 2 | NIH | 6/10/2019 | $0 |
| | 2019 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 001 | 2 | NIH | 6/17/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,524,770 ) |
| | 2018 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AT008312 | Harvesting specific plant metabolites from hairy root cultures using magnetized nanoparticles | 000 | 3 | NIH | 3/23/2018 | $498,691 |
| | 2018 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 001 | 2 | NIH | 8/2/2018 | $794,605 |
| | 2018 | 2018 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R43NS108804 | Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | 000 | 1 | NIH | 8/31/2018 | $231,474 |
| | 2018 | 2017 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 000 | 1 | NIH | 8/2/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,277,207 ) |
| | 2017 | 2017 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVENUE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 000 | 2 | NIH | 8/21/2017 | $489,617 |
| | 2017 | 2017 | NAPROGENIX, INC. | KTRDC-UK 1401 UNVERSITY DR | LEXINGTON | KY | 40546-0001 | FAYETTE | USA | R44AT008312 | Harvesting specific plant metabolites from hairy root cultures using magnetized nanoparticles | 000 | 2 | NIH | 3/28/2017 | $530,326 |
| | 2017 | 2017 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVENUE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | U44AA026126 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence | 000 | 1 | NIH | 8/24/2017 | $672,530 |
| | 2017 | 2015 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA018226 | Selection-driven plant metabolites for treatment of CNS diseases | 001 | 4 | NIH | 8/23/2017 | -$98,469 |
| | 2017 | 2014 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R41AT008312 | Harvesting specific plant metabolites from hairy root cultures using magnetized n | 000 | 1 | NIH | 11/23/2016 | -$66,894 |
| | 2017 | 2014 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R43AA021038 | Novel flavonoids as anti-inflammatory agents in alcoholism | 000 | 1 | NIH | 1/11/2017 | -$39,463 |
| | 2017 | 2014 | NAPROGENIX, INC. | UK-ASTECC 145 GRAHAM AVE | LEXINGTON | KY | 40506-0001 | FAYETTE | USA | R44AA018226 | Selection-driven plant metabolites for treatment of CNS diseases | 000 | 4 | NIH | 8/23/2017 | -$210,440 |
|
| Issue Date FY: 2016 ( Subtotal = $455,773 ) (Continued on the next page) |
| | 2016 | 2016 | NAPROGENIX INC | 1401 UNIVERSITY DRIVE | LEXINGTON | KY | 40546 | FAYETTE | USA | R44AA025804 | Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | 000 | 1 | NIH | 9/22/2016 | $455,773 |
|
